Long-term outcome in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation.
autologous transplantation
follicular lymphoma
minimal residual disease
relapse
second malignancy
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
15
07
2021
received:
28
05
2021
accepted:
16
07
2021
pubmed:
22
7
2021
medline:
9
2
2022
entrez:
21
7
2021
Statut:
ppublish
Résumé
To contribute data on long-term outcome and potential curative impact of ASCT in FL, especially following HDT with the BEAM protocol (BCNU, etoposide, cytarabine and melphalan), given very limited data on this topic in the literature. Patients with FL (n = 76) were treated in our institution with HDT and ASCT. In the case of long-term remission (≥8 years), peripheral blood was tested for minimal residual disease by t(14;18)- and IGH-PCR, including the last follow-up. 10-year overall survival, progression-free survival, and freedom from progression (FFP) after first-line ASCT (n = 20) were 80%, 60%, and 69%, after second-line ASCT (n = 48, following BEAM) 66%, 38%, and 41%, after third/fourth-line ASCT (n = 8) 33%, 25%, and 25%, respectively. Prognostic factors for FFP were treatment line and FLIPI (Follicular Lymphoma International Prognostic Index). 10-year FFP for second-line ASCT and low-risk FLIPI at relapse was 69%, intermediate-risk 28%, and high-risk 25% (P < .05). 26 patients developed sustained long-term clinical and molecular remissions of up to 27 years. Sustained long-term clinical and molecular complete remissions up to 27 years can be achieved following ASCT (including HDT with BEAM in second treatment line), indicating a potential curative impact of ASCT in FL.
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
543-552Subventions
Organisme : MRD analysis was funded partly by TRANSCAN V Novel 01KT1807 by BMBF
Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Pettengell R, Schmitz N, Gisselbrecht C, et al. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the european group for blood and marrow transplantation. J Clin Oncol. 2013;31:1624-1630.
Casulo C, Nastoupil L, Fowler NH, Friedberg JW, Flowers CR. Unmet needs in the first-line treatment of follicular Lymphoma. Ann Oncol. 2017;28:2094-2106.
Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM. Autologous transplantation in follicular lymphoma with early therapy failure: a NLCS and CIBMTR analysis. Biol Blood Marrow Transplant. 2018;24:1163-1171.
Nastoupil LJ, Flowers CR, Leonhard JP. Sequencing of therapies in relapsed follicular lymphoma. Hematology Am Soc Hematol Educ Program. 2018;2018(1):189-193.
Feugier P, Filliatre-Clement L. Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma. F100Research. 2019;8:294.
Matasar MJ, Luminari S, Barr PM, Barta SK, Danilov AV, Hill BT. Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs. Oncologist. 2019;24:e1236-e1250.
Sutamtewagul G, Link BK. Novel treatment approaches and future perspectives in follicular lymphoma. Ther Adv Hematol. 2019;10:1-20.
Jurinovic V, Metzner B, Pfreundschuh M, Schmitz N, Wandt H, Keller U. Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the german low grade lymphoma study group. Biol Blood Marrow Transplant. 2018;24:1172-1179.
Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Hernández-Garcia MT. Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the prerituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry. Bone Marrow Transplant. 2018;53:780-783.
Bruna R, Benedetti F, Boccomini C, Patti C, Barbui AM, Pulsoni A. Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial. Haematologica. 2019;104:2241-2248.
Pettengell R, Uddin R, Boumendil A, et al. Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial. Bone Marrow Transplant. 2021;56(6):1413-1421. https://doi.org/10.1038/s41409-020-01182-w. Online ahead of print
Apostolidis J, Gupta RK, Grenzelias D, et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol. 2000;8:527-536.
Ladetto M, Corradini P, Vallet S, et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood. 2002;100:1559-1565.
Corradini P, Ladetto M, Zallio F, et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol. 2004;22:1460-1468.
Hicks LK, Woods A, Buckstein R, et al. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant. 2009;43:701-708.
Kornacker M, Stumm J, Pott C, et al. Characteristics of relapse after autologous stem cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol. 2009;20:722-728.
Ladetto M, Lobetti-Bodoni C, Mantoan B, et al. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood. 2013;122:3759-3766.
Lobetti-Bodoni C, Mantoan B, Monitillo L, et al. Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma. Ther Adv Hematol. 2013;4:189-198.
Bishton M, Rule S, Wilson W, Turner D. The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival. Br J Haematol. 2020;190:545-554.
Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111:4004-4013.
Pott C, Schrader C, Gesk S, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood. 2006;107:2271-2278.
Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115:3215-3223.
Hirt C, Schüler F, Kiefer T, et al. Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients. Br J Haematol. 2008;141:631-640.
Smyth L, Buckstein R, Pennell N, et al. Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-a induces prolonged clinical and molecular remissions in patients with follicular lymphoma. Br J Haematol. 2019;184:469-472.
Rohatiner AZ, Nadler L, Davies AJ, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. 2007;25:2554-2559.
Montoto S, Canals C, Rohatiner AZ, et al. Long-term follow-up of high-dose treatment with autologous hematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia. 2007;21:2324-2331.
Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progressionfree survival in follicular lymphoma-results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Blood. 2004;104:2667-2674.
Metzner B, Pott C, Müller TH, et al. Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation. Ann Oncol. 2013;24:1609-1615.
van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia. 2003;17:2257-2317.
Berinstein N, Bhella S, Pennell N, et al. Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab. Ann Hematol. 2015;94:813-823.
Schaaf M, Reiser M, Borchmann P, et al. High-dose therapy followed by autologous purged stem cell transplantation versus chemotherapy or immunochemotherapy for follicular lymphoma in adults. Cochrane Database Syst Rev. 2012;1:CD007678.
Hamadani M, Horowitz MM. Allogeneic transplantation for follicular lymphoma: does one size fit all? J Oncol Pract. 2017;13:798-806.
Montoto S, Corradini P, Dreyling M, et al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica. 2013;98:1014-1021.
Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16:1111-1122.
Khouri IF, McLaughlin P, Saliba RM, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008;111:5530-5536.
Khouri IF. Allogeneic stem cell transplantation in follicular lymphoma. Best Pract Res Clin Haematol. 2011;24:271-277.
Smith SM, Godfrey J, Ahn KW, et al. Autologous versus allogeneic transplantation in follicular lymphoma patients experiencing early treatment failure. Cancer. 2018;124:2541-2551.
Dickinson M, Popplewell L, Kolstad A, et al. ELARA: a phase II, single-arm, multicenter, open-label trial investigating the efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma (r/r FL). J Clin Oncol. 2019;37(suppl 15):TPS 7573.
Hirayama AV, Gauthier J, Hay KA, et al. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood. 2019;134:636-640.
Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258-1264.
Montoto S, Lopez-Guillermo A, Altes A, et al. Predictive value of follicular lymphoma international prognostic index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol. 2004;15:1484-1489.
Buske C, Hoster E, Dreyling M, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108:1504-1508.